Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Real‐world weight‐loss effectiveness of glucagon‐like peptide‐1 agonists among patients with type 2 diabetes: A retrospective cohort study
Gretchen E. White, Ingrid Shu, David Rometo, et al.
Obesity (2023) Vol. 31, Iss. 2, pp. 537-544
Open Access | Times Cited: 25

Showing 25 citing articles:

Effectiveness and safety of drugs for obesity
Kristina H. Lewis, Caroline E Sloan, Daniel H. Bessesen, et al.
BMJ (2024), pp. e072686-e072686
Open Access | Times Cited: 20
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Children with Obesity: An Obesity Medicine Association (OMA) and Expert Joint Perspective 2025
Jennifer Panganiban, Mohit Kehar, Samar H. Ibrahim, et al.
Obesity Pillars (2025), pp. 100164-100164
Open Access | Times Cited: 1
Effectiveness and care continuity in an app‐based, glucagon‐like peptide‐1 receptor agonist‐supported weight‐loss service for women with overweight and obesity in the UK: A real‐world retrospective cohort analysis
Louis Talay, Matt Vickers
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 7, pp. 2984-2987
Closed Access | Times Cited: 10
Why People with Overweight and Obesity Are Seeking Care Through Digital Obesity Services: A Qualitative Analysis of Patients from Australia’s Largest Digital Obesity Provider
Louis Talay, Matt Vickers, Sarah Loftus
Telemedicine Reports (2024) Vol. 5, Iss. 1, pp. 187-194
Closed Access | Times Cited: 9
Effectiveness of an Email-Based, Semaglutide-Supported Weight-Loss Service for People with Overweight and Obesity in Germany: A Real-World Retrospective Cohort Analysis
Louis Talay, Matt Vickers, Laura Ruiz
Obesities (2024) Vol. 4, Iss. 3, pp. 256-269
Open Access | Times Cited: 6
Oral versus subcutaneous semaglutide weight loss outcomes after two years among patients with type 2 diabetes in a Real-World Database
Jimmy Kwon, Diana Thiara, Jonathan H. Watanabe
Expert Review of Endocrinology & Metabolism (2025), pp. 1-6
Closed Access
Therapeutic Potential of GLP-1 Receptor Agonists in Metabolic Associated Steatotic Liver Disease
Klaudia Nowak, Krzysztof Łupina, Anna Romac, et al.
Annals of Pharmacotherapy (2025)
Closed Access
Treating class 2–3 obesity with glucagon‐like peptide‐1 agonists: A 2‐year real‐world cohort study
Mona Abdel‐Bary, Andrea Bródy, Jochen Schmitt, et al.
Diabetes Obesity and Metabolism (2025)
Closed Access
Glucagon-like Peptide-1 Receptor Agonists and Capsule Endoscopy in Patients with Diabetes: A Matched Cohort Study
Tarek Odah, Asrita Vattikonda, Mark E. Stark, et al.
Gastrointestinal Endoscopy (2024)
Closed Access | Times Cited: 4
Cardiovascular outcomes of glucagon-like peptide-1 agonist in patients with obesity and hypertrophic cardiomyopathy
Ayman R. Fath, Amro Aglan, Martin S. Maron, et al.
International Journal of Cardiology (2025), pp. 133082-133082
Closed Access
GLP-1 Agonists for Weight Loss: Do They Increase Complications in Non-Diabetic Patients Undergoing Primary Total Hip Arthroplasty?
Jens T. Verhey, Roman Austin, Saad Tarabichi, et al.
The Journal of Arthroplasty (2025)
Closed Access
Oral Semaglutide in Type 2 Diabetes: Clinical–Metabolic Outcomes and Quality of Life in Real-World Practice
Paola Pantanetti, Vanessa Ronconi, Marco Sguanci, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 16, pp. 4752-4752
Open Access | Times Cited: 2
Sculpting Success: The Importance of Diet and Physical Activity to Support Skeletal Muscle Health During Weight Loss with New Generation Anti-Obesity Medications
Gregory J. Grosicki, Nikhil V. Dhurandhar, Jessica L. Unick, et al.
Current Developments in Nutrition (2024) Vol. 8, Iss. 11, pp. 104486-104486
Open Access | Times Cited: 2
Glucagon‐like peptide‐1 analogues in monogenic syndromic obesity: Real‐world data from a large cohort of Alström syndrome patients
Sadaf Ali, Shanat Baig, Subadra Wanninayake, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 3, pp. 989-996
Open Access | Times Cited: 6
Glucagon-like peptide-1 receptor agonist therapy effects on glycemic control and weight in a primary care clinic population
E. Paleček, Margaret M. Kimzey, Jingwen Zhang, et al.
Journal of Investigative Medicine (2024)
Closed Access | Times Cited: 1
Clinical Effects of Glucagon-Like Peptide-1 Agonist Use for Weight Loss in Women With Polycystic Ovary Syndrome: A Scoping Review
Melissa Frangie Machado, Taylor Shunk, Grace Hansen, et al.
Cureus (2024)
Open Access | Times Cited: 1
Comparative estimate of glucose-lowering therapies on risk of incident pneumonia and severe sepsis: an analysis of real-world cohort data
Alex E. Henney, David R. Riley, Theresa Hydes, et al.
Thorax (2024), pp. thorax-221906
Open Access | Times Cited: 1
Learn from failures and stay hopeful to GPR40, a GPCR target with robust efficacy, for therapy of metabolic disorders
Hong-Ping Guan, Yusheng Xiong
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 7
Assessment of nanoliposomes loaded with daidzein for ameliorating diabetes in alloxan-induced mice: A promising nutraceutical approach
N Rad, Ehsan Karimi, Homa Mahmoodzadeh Akherat, et al.
Journal of Functional Foods (2023) Vol. 110, pp. 105848-105848
Open Access | Times Cited: 3
What can functional brain imaging teach us about remission of type 2 diabetes?
Dhruti Hirani, Shahd Alabdulkader, Alexander D. Miras, et al.
Diabetic Medicine (2023) Vol. 40, Iss. 12
Open Access | Times Cited: 2
The effectiveness and sustainability of health outcomes from a holistic digital weight‐loss service with concomitant initiation of tirzepatide: A pragmatic randomized controlled trial in the UK
Louis Talay, Matt Vickers, Omar Alvi
Diabetes Obesity and Metabolism (2024) Vol. 26, Iss. 11, pp. 4854-4863
Open Access
Association between plausible genetic factors and weight loss from GLP1-RA and bariatric surgery: a multi-ancestry study in 10 960 individuals from 9 biobanks
J German, Mattia Cordioli, Veronica Tozzo, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Weight Trends After Spinal Cord Stimulation Therapy for Chronic Pain
Caroline Kremer, Assaf Berger, Kenneth Bernstein, et al.
Neuromodulation Technology at the Neural Interface (2024)
Closed Access
SGLT2i and GLP1RA effects in patients followed in a hospital diabetology consultation
António Cabral Lopes, Olga Lourenço, Manuel Morgado
Expert Review of Clinical Pharmacology (2024) Vol. 17, Iss. 11, pp. 1081-1088
Closed Access
Methylphenidate can help reduce weight, appetite, and food intake—a narrative review of adults’ anthropometric changes and feeding behaviors
Fernand Vedrenne‐Gutiérrez, Sangho Yu, Anna Olivé-Madrigal, et al.
Frontiers in Nutrition (2024) Vol. 11
Open Access
Page 1

Scroll to top